One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Longeveron  logo
Longeveron LGVN
$ 1.76 -3.3%
report update icon

Quarterly report 2026-Q2
added 08-12-2026

Longeveron Financial Statements 2025-2011 | LGVN

Annual Financial Statements Longeveron

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

16.9 B 14.4 B 1.26 B 61.2 M 141 M - - - - - - - - - -

Shares

17.6 B 9.41 B 2.17 B 21 M 18.9 M - - - - - - - - - -

Historical Prices

0.96 1.53 0.58 2.92 7.47 - - - - - - - - - -

Net Income

-22.7 M -16 M -21.4 M -18.8 M -17 M -3.72 M -2.96 M -6.34 M - - - - - - -

Revenue

1.2 M 2.39 M 709 K 1.22 M 1.31 M 5.63 M 5.64 M 2.13 M - - - - - - -

Cost of Revenue

396 K 508 K 488 K 725 K 716 K 3.8 M - - - - - - - - -

Gross Profit

803 K 1.88 M 221 K 497 K 590 K 1.83 M 1.75 M 681 K - - - - - - -

Operating Income

-23.3 M -16.5 M -21 M -18 M -17.5 M -3.78 M - - - - - - - - -

Interest Expense

680 K 549 K -377 K 1.4 M 411 K 57 K - - - - - - - - -

EBITDA

-22.5 M -15.8 M -20.3 M -17.3 M -17.5 M -2.99 M -2.23 M -5.61 M - - - - - - -

Operating Expenses

24.1 M 18.4 M 21.2 M 18.5 M 18 M 5.6 M 4.75 M 7.04 M - - - - - - -

General and Administrative Expenses

12 M 10.3 M 12.2 M 8.12 M 1 M 2.73 M 2.77 M 3.12 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Longeveron

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

15 M 24.8 B - 18.4 B 15 B 15 B - 13.6 B 6.51 B 2.51 B - 2.12 B 2.11 M 2.1 M - 21 M 20.9 M 20.9 M - 19.1 M 19 M 17.5 B - 16 M 16 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-5.03 M -4.74 M - -7.22 M -5.03 M -5.01 M - -4.42 M -3.41 M -4.06 M - -5.11 M -5.63 M -4.65 M - -5.24 M -5.62 M -3.51 M - -4.86 M -5.01 M -3.11 M - -2.36 M -1.22 M -3.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

316 K 398 K - 137 K 316 K 381 K - 773 K 468 K 548 K - 150 K 217 K 279 K - 265 K 466 K 370 K - 232 K 489 K 376 K - 1.86 M 876 K 1.71 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

170 K 134 K - 12 K 170 K 106 K - 91 K 124 K 219 K - 96 K 124 K 203 K - 173 K 306 K 205 K - 68 K 281 K 227 K - 1.49 M 764 K 896 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

146 K 264 K - 125 K 146 K 275 K - 682 K 344 K 329 K - 54 K 93 K 76 K - 92 K 160 K 165 K - 164 K 208 K 149 K - 373 K 112 K 812 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-5.4 M -4.78 M - -7.31 M -5.4 M -5.18 M - -4.65 M -3.5 M -4.09 M - -5.16 M -5.71 M -4.72 M - -5.19 M -4.22 M -3.39 M - -4.9 M -5.06 M -3.46 M - -958 K -1.23 M -213 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

369 K 39 K - 89 K 369 K 170 K - 230 K 87 K 32 K - 55 K 80 K 69 K - 1 K -1.4 M -116 K - 1 K 2 K 347 K - 20 K 10 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-5.2 M -4.58 M - -7.11 M -5.2 M -4.98 M - -4.45 M -3.3 M -3.89 M - -4.96 M -5.51 M -4.52 M - -4.99 M -4.02 M -3.29 M - -4.7 M -4.96 M -3.26 M - -368 K -834 K -13 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

5.54 M 5.04 M - 7.44 M 5.54 M 5.46 M - 5.33 M 3.84 M 4.42 M - 5.22 M 5.8 M 4.79 M - 5.28 M 4.38 M 3.56 M - 5.07 M 5.27 M 3.61 M - 1.33 M 1.34 M 1.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

2.59 M 2.72 M - 3.58 M 2.59 M 2.94 M - 3.12 M 2.12 M 2.2 M - 3.37 M 3.52 M 2.01 M - 2.07 M 2.43 M 1.98 M - 3 M 3.26 M 1.71 M - 702 K 649 K 686 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Longeveron LGVN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Longeveron plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
Verastem Verastem
VSTM
$ 9.38 -4.82 % $ 650 M usaUSA
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
- - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.0 -7.62 % $ 620 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 156.5 -2.85 % $ 20.5 B usaUSA
Amgen Amgen
AMGN
$ 462.71 -3.3 % $ 249 B usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 7.72 -11.26 % $ 2.76 M usaUSA
Biogen Biogen
BIIB
$ 243.85 -4.17 % $ 35.7 B usaUSA
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 4.03 6.9 % $ 652 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.01 -4.14 % $ 109 M usaUSA
Mustang Bio Mustang Bio
MBIO
$ 0.39 -5.63 % $ 1.91 M usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.77 -4.07 % $ 1.15 B usaUSA